206 related articles for article (PubMed ID: 23122841)
21. Treatment with the PARP-inhibitor PJ34 causes enhanced doxorubicin-mediated cell death in HeLa cells.
Magan N; Isaacs RJ; Stowell KM
Anticancer Drugs; 2012 Jul; 23(6):627-37. PubMed ID: 22293659
[TBL] [Abstract][Full Text] [Related]
22. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
Matsumoto Y; Takano H; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
[TBL] [Abstract][Full Text] [Related]
23. Nitric oxide inhibits topoisomerase II activity and induces resistance to topoisomerase II-poisons in human tumor cells.
Kumar A; Ehrenshaft M; Tokar EJ; Mason RP; Sinha BK
Biochim Biophys Acta; 2016 Jul; 1860(7):1519-27. PubMed ID: 27095671
[TBL] [Abstract][Full Text] [Related]
24. Decreased nucleotide excision repair activity and alterations of topoisomerase IIalpha are associated with the in vivo resistance of a P388 leukemia subline to F11782, a novel catalytic inhibitor of topoisomerases I and II.
Kruczynski A; Barret JM; Van Hille B; Chansard N; Astruc J; Menon Y; Duchier C; Créancier L; Hill BT
Clin Cancer Res; 2004 May; 10(9):3156-68. PubMed ID: 15131057
[TBL] [Abstract][Full Text] [Related]
25. Loss of protein kinase Cδ/HuR interaction is necessary to doxorubicin resistance in breast cancer cell lines.
Latorre E; Castiglioni I; Gatto P; Carelli S; Quattrone A; Provenzani A
J Pharmacol Exp Ther; 2014 Apr; 349(1):99-106. PubMed ID: 24492650
[TBL] [Abstract][Full Text] [Related]
26. Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs.
Trinh BQ; Ko SY; Barengo N; Lin SY; Naora H
Cancer Res; 2013 Jan; 73(2):1000-10. PubMed ID: 23222298
[TBL] [Abstract][Full Text] [Related]
27. Cellular resistance against the novel hybrid anthracycline N-(2-chloroethyl)-N-nitrosoureidodaunorubicin (AD 312) is mediated by combined altered topoisomerase II and O6-methylguanine-DNA methyltransferase activities.
Pawlik CA; Israel M; Sweatman TW; Lothstein L
Oncol Res; 1998; 10(4):209-17. PubMed ID: 9778692
[TBL] [Abstract][Full Text] [Related]
28. TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma.
Jain M; Zhang L; He M; Zhang YQ; Shen M; Kebebew E
Endocr Relat Cancer; 2013 Jun; 20(3):361-70. PubMed ID: 23533247
[TBL] [Abstract][Full Text] [Related]
29. O6-methylguanine-DNA methyltransferase (MGMT) transfectants of a 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-sensitive colon cancer cell line selectively repopulate heterogenous MGMT+/MGMT- xenografts after BCNU and O6-benzylguanine plus BCNU.
Phillips WP; Willson JK; Markowitz SD; Zborowska E; Zaidi NH; Liu L; Gordon NH; Gerson SL
Cancer Res; 1997 Nov; 57(21):4817-23. PubMed ID: 9354444
[TBL] [Abstract][Full Text] [Related]
30. Topoisomerase levels determine chemotherapy response in vitro and in vivo.
Burgess DJ; Doles J; Zender L; Xue W; Ma B; McCombie WR; Hannon GJ; Lowe SW; Hemann MT
Proc Natl Acad Sci U S A; 2008 Jul; 105(26):9053-8. PubMed ID: 18574145
[TBL] [Abstract][Full Text] [Related]
31. DNA damage response (DDR) induced by topoisomerase II poisons requires nuclear function of the small GTPase Rac.
Wartlick F; Bopp A; Henninger C; Fritz G
Biochim Biophys Acta; 2013 Dec; 1833(12):3093-3103. PubMed ID: 23999236
[TBL] [Abstract][Full Text] [Related]
32. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
[TBL] [Abstract][Full Text] [Related]
33. Antitumor activity of XR5944, a novel and potent topoisomerase poison.
Stewart AJ; Mistry P; Dangerfield W; Bootle D; Baker M; Kofler B; Okiji S; Baguley BC; Denny WA; Charlton PA
Anticancer Drugs; 2001 Apr; 12(4):359-67. PubMed ID: 11335793
[TBL] [Abstract][Full Text] [Related]
34. Down-regulation of human topoisomerase IIalpha expression correlates with relative amounts of specificity factors Sp1 and Sp3 bound at proximal and distal promoter regions.
Williams AO; Isaacs RJ; Stowell KM
BMC Mol Biol; 2007 May; 8():36. PubMed ID: 17511886
[TBL] [Abstract][Full Text] [Related]
35. Biological evaluation of a halogenated triterpenoid, 2α-bromo-dihydrobelulonic acid as inhibitor of human topoisomerase IIα and HeLa cell proliferation.
Ghosh S; Mukhopadhyay S; Sarkar M; Mandal A; Das V; Kumar A; Giri B
Chem Biol Interact; 2017 Apr; 268():68-76. PubMed ID: 28254521
[TBL] [Abstract][Full Text] [Related]
36. Ataxia telangiectasia mutated-dependent regulation of topoisomerase II alpha expression and sensitivity to topoisomerase II inhibitor.
Tamaichi H; Sato M; Porter AC; Shimizu T; Mizutani S; Takagi M
Cancer Sci; 2013 Feb; 104(2):178-84. PubMed ID: 23163762
[TBL] [Abstract][Full Text] [Related]
37. Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms.
Deng S; Yan T; Jendrny C; Nemecek A; Vincetic M; Gödtel-Armbrust U; Wojnowski L
BMC Cancer; 2014 Nov; 14():842. PubMed ID: 25406834
[TBL] [Abstract][Full Text] [Related]
38. Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells.
Pourpak A; Landowski TH; Dorr RT
J Pharmacol Exp Ther; 2007 Jun; 321(3):1109-17. PubMed ID: 17351106
[TBL] [Abstract][Full Text] [Related]
39. Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line.
Son YS; Suh JM; Ahn SH; Kim JC; Yi JY; Hur KC; Hong WS; Muller MT; Chung IK
Cancer Chemother Pharmacol; 1998; 41(5):353-60. PubMed ID: 9523730
[TBL] [Abstract][Full Text] [Related]
40. HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.
Fountzilas G; Valavanis C; Kotoula V; Eleftheraki AG; Kalogeras KT; Tzaida O; Batistatou A; Kronenwett R; Wirtz RM; Bobos M; Timotheadou E; Soupos N; Pentheroudakis G; Gogas H; Vlachodimitropoulos D; Polychronidou G; Aravantinos G; Koutras A; Christodoulou C; Pectasides D; Arapantoni P
J Transl Med; 2012 Jan; 10():10. PubMed ID: 22240029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]